# Amgen drops ph. 1 obesity drug, upping pressure on MariTide

> **Newsylist Open Intelligence Dossier** · First detected: 2026-08-05 02:29 UTC · Category: Business · Sources: 10 · Current Velocity: 7.91

## Intelligence Brief
"Amgen drops ph. 1 obesity drug, upping pressure on MariTide" developed substantial multi-source reporting across the Business sector, tracked across 10 distinct newsrooms by Newsylist.


Key reporting was led by qz.com, PR Newswire, Breakingthenews.net and FirstWord PHARMA. Coverage velocity and cross-outlet momentum were measured using Newsylist open coverage telemetry.


Synthesized from multi-source international reporting and live coverage telemetry under Newsylist open intelligence methodology.

## Verified Facts & Key Claims
### What drove coverage for Amgen drops ph. 1 obesity drug, upping pressure on MariTide?
Coverage spiked when 10 independent newsrooms published 10 verified reports during this coverage cycle.

### How did Newsylist track this trend?
Newsylist monitored article arrival rates, source diversity, and cross-outlet validation in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| qz.com | Amgen Q2 2026 earnings beat, raises full-year outlook, drops AMG 513 | 2026-08-04 20:23 | [Source Link](https://news.google.com/rss/articles/CBMigwFBVV95cUxPY1VtQWRMdWN0LXluYTIxTDlKVWRrZnFseGFBV2l6UzA5dFdXM1hQTXNCdHUwX29sUzFyZU5qLVhETDJ4U1ktQWpiUVFCT3Z0QjJ0OXo3SWswQWpoWlRRNDV4bnVLcjNfcEtUOUo4MWh0Tko5Z0tkQjlZYTl1NGFZZDJkOA?oc=5) |
| PR Newswire | AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS | 2026-08-04 20:23 | [Source Link](https://news.google.com/rss/articles/CBMiqwFBVV95cUxQX1ZISlctV0dzM1p1MzlNUmVjTG5xeDdKMGZQcDNYX3k5WFRTVnZZdXp3OUw0RkEwa3JwQWxoVXdWQmJEUFp1Zk5NRXdWWXQyUUVScDAydFZWM3ZoQ2pSQ2x6WTRoMnNZUnNlaWpBbGRfcGtPMHY1Ny1NNWtKQ0pqUUkzaGpYU2RpNDlhYjlobFZQYVd3MjNHV3pqcDA3VE1GSi1ncGpVWEUxZUU?oc=5) |
| Breakingthenews.net | Amgen Q2 revenue tops projections at $10.1B, up 10% | 2026-08-04 20:23 | [Source Link](https://news.google.com/rss/articles/CBMilwFBVV95cUxPcDhrUHNoNTJJU2VXeVJGNjgzYXkza0ZVS09iUS1lZWUwYmFDdHV2T1JtVUwxYTBWWDBYMmVoS3U4d1RDSVFoMXRNa1FlZVJJLXFmc1ljaHpiSTZ2LWhVUkZmdTR5VWx5ZHJRZWQ4d0s0dHM3Uzhxei1HRTNlNUdaR3FrZ1o4RWNVQ0lrSldibE5kcHhpeTdJ?oc=5) |
| FirstWord PHARMA | Amgen remains bullish on Repatha, axes obesity asset in 2Q report | 2026-08-04 20:23 | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE5lZE1KeE0xZEd4aVEyU3ZlN0VZcm9QcmZ4Qm5FZ0lpUDJGSzM2TERFeGthRmhRY2ROYVF6WG9xU01VMlNGX3VDTHNaSHdMNHc0NGg4?oc=5) |
| Yahoo Finance | Amgen (AMGN) To Report Earnings Tomorrow: Here Is What To Expect | 2026-08-04 20:23 | [Source Link](https://news.google.com/rss/articles/CBMiogFBVV95cUxNcVVhSTdJM0dYVmEwTGtMQ25ZdV9PZC1HZkRVaHItanJUeFozMF9mNGxicFl6S0RzNFJjQzlYcXBnM18yOC1wRVkzaFFlODBJMFhfV3FQQjBheTNkYjFOT0llY2dfeEMybHN2NG5PekRhVmFfd2hUX1RGMUVzdm0ya1hBNVlrMHpJRzRQQVJkaXNxenQ4blN6R0xVampaV1V0WEE?oc=5) |
| Bloomberg.com | Amgen Lifts Outlook After Blockbuster Sales Top Expectations | 2026-08-04 20:23 | [Source Link](https://news.google.com/rss/articles/CBMisAFBVV95cUxOS2Q3VTJhRmJJOVJhemh1RlFwcWdqWGVwRFZfQ1VJVjllOUx0QjJESVJyMEROeUZxU0huakRYVkQ0R2FLbTlvaXZFQnBiUWY2NGtFbTZTM0hqWTBoaXhmTm1SNGVVSFJPQkJLam9wYXprdmZqamxqdFNUYm0yTnBUWWZGY2pLT05lemh1TkNNd0lZQmhldTFtbHA2VW1IbUdfQnBvTzAzT2pSbDhKRFVpWg?oc=5) |
| Investor's Business Daily | Amgen Boosts Sales View By $1 Billion After Smashing Views | 2026-08-04 20:23 | [Source Link](https://news.google.com/rss/articles/CBMigwFBVV95cUxQSFVxUWRiaTRpakEwWklpdWdubmtRUjUtTVhCT0d2aUxYRHZ1Nml0ZEFUYUJKVlNjV0xWUDA5Xy1CMGduUHY4ZEVzeFNVLU5SaWVXS1FOOWZTODBhUWNRLV8wTndjNE55QnVRb2kxbEZxeXVuMXI4UkxkSG8yTUd0VWtRMA?oc=5) |
| Fierce Pharma | Amgen rides Repatha renaissance as cardio wins keep cholesterol med's momentum rolling | 2026-08-04 20:23 | [Source Link](https://news.google.com/rss/articles/CBMiugFBVV95cUxPaW9BNDJKd3c2cGcxX3d1bnE3azZBSF8zN045ZHdYaFd3Tkx0WlhSMG1QTnJheDdzRDVRanJ6SW84U3RYY2NrdHhwSTlrY2ZNLXdxZ2sxM3VKYXkzWTFfRUJNdmVEVjRPSExoa01GelAteWVLeGVZTnAxWjdkREtrZGFrMjJ1QzkwLVprY3lrZzdyU1M3UEM0SVBMUlFzdjNBXzdHUE0yNGZ1dGZFaXpod2JsTDRTd3NTMVE?oc=5) |
| WSJ | Amgen Lifts Outlook on Strong Drug Sales, to End Early Development of Obesity Treatment | 2026-08-04 20:23 | [Source Link](https://news.google.com/rss/articles/CBMizgFBVV95cUxQNzFRRU5LeWlyZy1WcGEtVC1UYjRWSFZTeG03NDdrNFE1NTVRWlVlSGFld0E4NFhFUHJBMnp1aDlKLWM5NUdVRndvcDlaenhCVDFGYW03LXJZQUp2NkFLbDk5SlhuRjZ0eTNtMnJ5ODBSbWU2d2pYdUpvQ3NOSDlGQmxqVTZZajc4bjFSazByMGtfQWtKVmtnT1kxdVFYZENFcG1udU00d1lkUXlnMkc4cHBtb0VjNzZzaFdGUmU0YkxDY2dYeVdIdGZ0M05TZw?oc=5) |
| Fierce Biotech | Amgen drops ph. 1 obesity drug, upping pressure on MariTide | 2026-08-04 20:23 | [Source Link](https://news.google.com/rss/articles/CBMioAFBVV95cUxPTllQeUpSUVFQdm1fd3ZsbGZZR0x3REJ0cUNZeDdzUGhEUndsX1ZUUXpSZmpEeVR4c0o1TXVaQzJhSGh0alhLNkU2N0QxQ0dGbENwRXZVb1ljN3ZEMEtqSDRYbER0NGVEXzVfa0ZscEFHNm9zMTVBZ1Vza2c4dU12aUY5dF9qTGdpYTBGazlJMzRxSnFXd2VySjNlS2VZckxI?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-08-05/amgen-drops-ph-1-obesity-drug-upping-pressure-on-maritide*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*